Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Qing Li

Matched on ORCID iD 0000-0002-3579-5494; OpenAlex author ID A5100404086. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 13

  1. Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenoc… Co-author DOI 10.1002/advs.202511726↗
  2. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Co-author DOI 10.1016/j.bbrc.2023.149426↗
  3. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  4. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  5. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41388-021-02159-9↗
  6. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  7. Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41419-021-04391-3↗
  8. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  9. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  10. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. Co-author DOI 10.1002/jcb.29433↗
  11. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  12. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Co-author DOI 10.1158/1078-0432.ccr-18-2297↗
  13. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Co-author DOI 10.1016/j.bbrc.2018.03.194↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li-Peng Hu · 13 shared papers, 2018–2025 · strength 1.62
  2. Shu‐Heng Jiang · 12 shared papers, 2018–2025 · strength 1.51
  3. Zhigang Zhang · 10 shared papers, 2018–2024 · strength 1.13
  4. Yongwei Sun · 9 shared papers, 2018–2024 · strength 1.08
  5. Minwei Yang · 6 shared papers, 2018–2024 · strength 0.71
  6. Qin Yang · 5 shared papers, 2019–2023 · strength 0.52
  7. Lili Zhu · 4 shared papers, 2018–2024 · strength 0.52
  8. Dongxue Li · 3 shared papers, 2022–2025 · strength 0.47
  9. Xu Wang · 4 shared papers, 2021–2023 · strength 0.46
  10. Xiaomei Yang · 3 shared papers, 2021–2025 · strength 0.43
  11. Gary Guishan Xiao · 4 shared papers, 2019–2023 · strength 0.40
  12. Yu-Heng Zhu · 2 shared papers, 2024–2025 · strength 0.38
  13. Hong‐Fei Yao · 2 shared papers, 2024–2025 · strength 0.38
  14. Yan‐Miao Huo · 3 shared papers, 2020–2024 · strength 0.36
  15. Xueli Zhang · 3 shared papers, 2021–2022 · strength 0.32
  16. Linli Yao · 3 shared papers, 2021–2022 · strength 0.32
  17. Dejun Liu · 2 shared papers, 2022–2024 · strength 0.30
  18. Xiaoyan Cao · 2 shared papers, 2018–2024 · strength 0.29
  19. Dejun Liu · 3 shared papers, 2020–2021 · strength 0.28
  20. Rongkun Li · 2 shared papers, 2020–2021 · strength 0.23
  21. Yifan Zhang · 2 shared papers, 2021–2022 · strength 0.23
  22. Hui Nie · 2 shared papers, 2021–2022 · strength 0.23
  23. Luju Jiang · 1 shared paper, 2025 · strength 0.21
  24. Shan Zhang · 1 shared paper, 2025 · strength 0.21
  25. Shuqi Cai · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.